Inhibitor of apoptosis proteins (IAPs) negatively regulate apoptosis and modulate immune and inflammatory responses, which are frequently dysregulated in cancer. Cellular IAPs (including cIAP1 and cIAP2) and X-linked IAP (XIAP) play a crucial role in the inhibition of apoptosis by inhibiting members of the caspase family via the death receptor–mediated and mitochondria-mediated pathways. Tumor cells can resist apoptosis by increasing the expression of proteins blocking pro-apoptotic pathways, such as cellular IAPs and XIAP. IAPs are also known to have a critical role in primary and secondary resistance to anticancer agents. Therefore, the inhibition of IAPs is considered a viable therapeutic target.1,2
Xevinapant is an investigational oral, small-molecule antagonist of IAPs, including
This is a phase III randomized, double-blind, placebo-controlled study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with histologically confirmed, locally advanced SCCHN. The study will assess event-free survival, as well as progression-free survival, overall survival, locoregional control, and safety.3LEARN ABOUT COMPANY SPONSORED CLINICAL TRIALS LEARN ABOUT ALL CLINICAL TRIALS
Are you interested in learning more about a clinical trial program investigating whether blocking inhibitor of apoptosis proteins might improve the efficacy of chemoradiotherapy? Visit our partner Debiopharma’s website to learn about our active and enrolling phase 3 trial.LEARN MORE ABOUT THE CLINICAL TRIAL
EGFR/MUC1, epidermal growth factor receptor/mucin 1; MET, mesenchymal epithelial transition factor.